Pfizer’s Obesity Pipeline Poised to Challenge Novo Nordisk
Pfizer is quietly building a GLP-1 obesity pipeline that could alter the competitive landscape, while investors seek ...
Which Investors Should Avoid Robo Advisors outlines situations where automated options may underperform. This intro highlights alternatives to consider.
28,175 articlesPfizer is quietly building a GLP-1 obesity pipeline that could alter the competitive landscape, while investors seek ...
Get a clear, investor-friendly view of Perion's 2025 earnings outlook. This guide explains revenue drivers, margins, ...
A bitcoin miner is branching into AI infrastructure, and the market has taken notice. The plan to turn U.S. sites int...
Oracle’s $523 billion backlog raises timing concerns as capex surges. cnbc’s deirdre bosa warns that the chip upgrade...
Three growth-focused ETFs are drawing fresh attention from analysts who see the potential for triple-digit upside if ...
Looking for steady income in a volatile market? This guide highlights three high-yield energy stocks march investors ...
LifeStance Health Group stunned the market with a beat-and-raise quarter, sending its stock up roughly 20%. This deep...
As Oracle prepares to report its Q4 2026 results, investors are weighing the cloud growth story, AI bets, and margin ...
When the Federal Reserve keeps rates unchanged, big retailers can swing on a dime. This article dives into why home d...
Intuitive Surgical dominates robotic-assisted surgery, and its moat is getting stronger. This piece breaks down why t...
As volatility stays elevated, a hedge against rising option premiums is gaining attention. The 8%-yield S&P 500 Premi...
Three giants of U.S. banking posted strong Q1 results, yet each faces a different market reality. JPMorgan sits near ...